1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 26, 1999
LA JOLLA PHARMACEUTICAL COMPANY
- --------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 0-24274 33-0361285
- --------------------------------------------------------------------------------
(STATE OR OTHER (COMMISSION (I.R.S. EMPLOYER
JURISDICTION OF FILE NUMBER) IDENTIFICATION NO.)
INCORPORATION)
6455 Nancy Ridge Drive San Diego, CA 92121
- --------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (619) 452-6600
- --------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
2
ITEM 5. OTHER EVENTS
On May 26, 1999, La Jolla Pharmaceutical Company issued a press
release announcing the extension by one year of the life of the
Company's warrants and an option, granted to the underwriter of the
Company's initial public offering, to purchase shares of the
Company's common stock and warrants.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to General Instruction F of Form 8-K, the following
document is incorporated by reference herein and attached as an
exhibit hereto:
EXHIBIT DESCRIPTION
------- -----------
99.1 La Jolla Pharmaceutical Company press release of May 26,
1999 regarding the Company's extension by one year of
the life of the Company's warrants and an underwriter
option to purchase shares of the Company's common stock
and warrants.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
La Jolla Pharmaceutical Company
(Registrant)
Date: May 27, 1999 By: /s/ Wood C. Erwin
------------------------------------
(Signature)
Name: Wood C. Erwin
Title: Chief Financial Officer
4
LA JOLLA PHARMACEUTICAL COMPANY
INDEX TO EXHIBITS
EXHIBIT
NUMBER EXHIBIT
- ------- -------
99.1 La Jolla Pharmaceutical Company press release of May 26, 1999
regarding the Company's extension by one year of the life of the
Company's warrants and an underwriter option to purchase shares of
the Company's common stock and warrants.